Cargando…
Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
INTRODUCTION: Lenvatinib is approved in Japan for treating patients with all histological subtypes of unresectable thyroid cancer, including differentiated thyroid cancer (DTC), medullary thyroid cancer (MTC), and anaplastic thyroid cancer (ATC). However, safety and effectiveness data are limited in...
Autores principales: | Takahashi, Shunji, Tahara, Makoto, Ito, Koichi, Tori, Masayuki, Kiyota, Naomi, Yoshida, Katsutoshi, Sakata, Yukinori, Yoshida, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444395/ https://www.ncbi.nlm.nih.gov/pubmed/32676927 http://dx.doi.org/10.1007/s12325-020-01433-8 |
Ejemplares similares
-
Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017) -
Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017) -
Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance
por: Tahara, Makoto, et al.
Publicado: (2021) -
Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
por: Furuse, Junji, et al.
Publicado: (2023) -
Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome
por: Fuchigami, Akira, et al.
Publicado: (2020)